Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference

information fournie par Boursorama •07/11/2018 à 18:00

Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference


Strasbourg, France – November 7th, 2018, 6:00 pm CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, presents its broad viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA).

.../...